Enliven Therapeutics Chief Medical Officer Helen Louise Collins reports sale of $234,203.1101 in common sharesPUBT·Nov 19, 2026 at 10:08 PMELVN+0.26%
ELVN: Second-line-plus phase III launch is imminent, with a potential early-2029 readoutQuartr·Nov 17, 2026 at 06:09 PMELVN+0.26%
Analysts Are Bullish on Top Healthcare Stocks: SCYNEXIS (SCYX), Enliven Therapeutics (ELVN)businessinsider·Nov 7, 2026 at 06:28 AMELVN+0.26%SCYX-8.64%
12 Health Care Stocks Moving In Friday's After-Market Sessionbenzinga_article·Nov 6, 2026 at 09:05 PMELVN+0.26%KPTI0.00%
Enliven Therapeutics (ELVN) Gets a Buy from Stifel NicolausTip Ranks·Nov 5, 2026 at 09:47 PMELVN+0.26%
Enliven Therapeutics Appoints Kristine Ball to Board of DirectorsPUBT·Nov 5, 2026 at 09:21 PMELVN+0.26%
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock Has Consensus Target Price of $75.44Market Beat·Oct 29, 2026 at 08:44 AMELVN+0.26%
Enliven Therapeutics Chief Medical Officer Helen Louise Collins Reports Sale of $192,342 in Common SharesPUBT·Oct 21, 2026 at 09:52 PMELVN+0.26%
Enliven Therapeutics (ELVN) Wins FDA Trial Alignment, Is The Upside Already Priced In?Simplywall·Oct 20, 2026 at 03:13 AMELVN+0.26%
HC Wainwright & Co. maintains Buy rating on Enliven Therapeutics, $73 price targetTradingView·Oct 19, 2026 at 10:27 AMELVN+0.26%